These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 36943653)
1. Combining serum AFP and CEUS LI-RADS for better diagnostic performance in Chinese high-risk patients. Gong W; Wu J; Wei H; Jiang Z; Wan M; Wu C; Xue W; Ma R; Zhou X; Zhou H Radiol Med; 2023 Apr; 128(4):393-401. PubMed ID: 36943653 [TBL] [Abstract][Full Text] [Related]
2. The Value of CEUS LI-RADS combined with AFP in early diagnosis of hepatocellular carcinoma in low- and high-risk patients. Wu Y; Chen Y; Wei L; Ding Z; Zhao S; Bao S; Tang J; Li H; Liu J; Zhu S J Cancer Res Ther; 2024 Aug; 20(4):1274-1283. PubMed ID: 38958652 [TBL] [Abstract][Full Text] [Related]
3. An assessment of liver lesions using a combination of CEUS LI-RADS and AFP. Li CQ; Huang H; Ruan SM; Hu HT; Xian MF; Xie XY; Lu MD; Kuang M; Wang Y; Chen LD Abdom Radiol (NY); 2022 Apr; 47(4):1311-1320. PubMed ID: 35122491 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma. Huang JY; Li JW; Lu Q; Luo Y; Lin L; Shi YJ; Li T; Liu JB; Lyshchik A Radiology; 2020 Feb; 294(2):329-339. PubMed ID: 31793849 [TBL] [Abstract][Full Text] [Related]
5. CEUS LI-RADS in Combination With the Serum Biomarker-Based ASAP Model Improves the Diagnostic Performance of HCC in High-Risk Patients. Wen R; Peng Y; Liang Y; Wu Y; Li H; Chen Y; Qin Y; Wen Z; Cui H; He Y; Yang H Ultrasound Med Biol; 2024 Nov; 50(11):1739-1744. PubMed ID: 39181805 [TBL] [Abstract][Full Text] [Related]
6. MR versus CEUS LI-RADS for Distinguishing Hepatocellular Carcinoma from other Hepatic Malignancies in High-Risk Patients. Huang Z; Zhou P; Li S; Li K Ultrasound Med Biol; 2021 May; 47(5):1244-1252. PubMed ID: 33610338 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of contrast-enhanced ultrasound LI-RADS version 2017: application on 271 liver nodules in individuals with non-alcoholic steatohepatitis. Huang Z; Zhou P; Li S; Li K Eur Radiol; 2022 Oct; 32(10):7146-7154. PubMed ID: 35639147 [TBL] [Abstract][Full Text] [Related]
8. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules. Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F; J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247 [TBL] [Abstract][Full Text] [Related]
9. Differentiating malignant and benign focal liver lesions in children using CEUS LI-RADS combined with serum alpha-fetoprotein. Jiang ZP; Zeng KY; Huang JY; Yang J; Yang R; Li JW; Qiu TT; Luo Y; Lu Q World J Gastroenterol; 2022 Jun; 28(21):2350-2360. PubMed ID: 35800178 [TBL] [Abstract][Full Text] [Related]
10. Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS. Ding J; Long L; Zhang X; Chen C; Zhou H; Zhou Y; Wang Y; Jing X; Ye Z; Wang F Eur Radiol; 2021 Feb; 31(2):847-854. PubMed ID: 32803416 [TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS. Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394 [TBL] [Abstract][Full Text] [Related]
12. Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis. Vidili G; Arru M; Solinas G; Calvisi DF; Meloni P; Sauchella A; Turilli D; Fabio C; Cossu A; Madeddu G; Babudieri S; Zocco MA; Iannetti G; Di Lembo E; Delitala AP; Manetti R World J Gastroenterol; 2022 Jul; 28(27):3488-3502. PubMed ID: 36158272 [TBL] [Abstract][Full Text] [Related]
13. Using new criteria to improve the differentiation between HCC and non-HCC malignancies: clinical practice and discussion in CEUS LI-RADS 2017. Zeng D; Xu M; Liang JY; Cheng MQ; Huang H; Pan JM; Huang Y; Tong WJ; Xie XY; Lu MD; Kuang M; Chen LD; Hu HT; Wang W Radiol Med; 2022 Jan; 127(1):1-10. PubMed ID: 34665430 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma. Li S; Zhou L; Chen R; Chen Y; Niu Z; Qian L; Fang Y; Xu L; Xu H; Zhang L Clin Radiol; 2021 Feb; 76(2):161.e1-161.e10. PubMed ID: 33198943 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Time Difference Method in Identifying Hepatocellular Carcinoma in Current CEUS LR-M Category Nodules. Shao LJ; Wang YJ; Yin SS; Jiang BB; Liu YH; Wang JC; Yang W; Wu W; Yan K Ultrasound Med Biol; 2024 Apr; 50(4):502-508. PubMed ID: 38246805 [TBL] [Abstract][Full Text] [Related]
16. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma? Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068 [TBL] [Abstract][Full Text] [Related]
17. Impact of Revision of the LR-M Criteria on the Diagnostic Performance of Contrast-Enhanced Ultrasound LI-RADS. Ding J; Qin Z; Zhou Y; Zhou H; Zhang Q; Wang Y; Jing X; Wang F Ultrasound Med Biol; 2021 Dec; 47(12):3403-3410. PubMed ID: 34598799 [TBL] [Abstract][Full Text] [Related]
18. Performance of current versus modified CEUS LI-RADS in the diagnosis of non-hepatocellular carcinoma malignancies. Wen R; Huang F; Lin P; Gao R; Pang J; Wu Y; Yin H; Tang Z; Ma Z; He Y; Yang H Abdom Radiol (NY); 2023 Dec; 48(12):3688-3695. PubMed ID: 37726380 [TBL] [Abstract][Full Text] [Related]
19. The interreader agreement and validation of contrast-enhanced ultrasound liver imaging reporting and data system. Li J; Ling W; Chen S; Ma L; Yang L; Lu Q; Luo Y Eur J Radiol; 2019 Nov; 120():108685. PubMed ID: 31606712 [TBL] [Abstract][Full Text] [Related]
20. Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Yang J; Zhang YH; Li JW; Shi YY; Huang JY; Luo Y; Liu JB; Lu Q World J Gastroenterol; 2020 Dec; 26(46):7325-7337. PubMed ID: 33362387 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]